Study finds oral tramadol-dipyrone combo improved pain control in dogs
Bottom line
A randomized clinical trial published in Frontiers in Veterinary Science found that a fixed-dose oral tramadol–dipyrone combination outperformed tramadol alone or dipyrone alone for early postoperative pain control in 30 client-owned female dogs undergoing ovariohysterectomy plus unilateral mastectomy. Dogs were randomized 1:1:1, all received meloxicam plus an initial IV dose of their assigned treatment at the end of surgery, and then started oral dosing about eight hours later every eight hours for five days. The combination group had lower pain scores than dipyrone alone on the afternoon after surgery, a higher proportion of pain-free dogs early in recovery, no need for rescue analgesia after oral treatment began, and no clinically relevant adverse effects reported. (frontiersin.org)
Why it matters: For veterinary teams managing painful soft-tissue oncology and reproductive procedures, the study adds evidence for a multimodal, take-home oral option that may improve the first postoperative day, when breakthrough pain can be hardest to control. That’s notable because tramadol’s role in dogs has been debated, and prior guidance and expert discussions have often treated it as a weaker or less reliable standalone choice. The new data suggest the tramadol–dipyrone pairing may perform better than either agent alone when layered into a broader protocol that already includes meloxicam. U.S. clinicians should also keep the regulatory context in mind: FDA notes dipyrone has an approved injectable animal product, Zimeta, that may be used extralabel in dogs under applicable rules, but this study evaluated a fixed-dose combination product used in Brazil, not a U.S.-labeled oral canine product. (frontiersin.org)
What to watch: Whether larger studies, U.S.-relevant formulations, and procedure-specific trials confirm the benefit and help define where this combination fits in postoperative discharge protocols. (frontiersin.org)
Key facts
- Study type
- Randomized clinical trial
- Journal
- Frontiers in Veterinary Science
- Sample size
- 30 client-owned female dogs
- Procedures
- Ovariohysterectomy plus unilateral mastectomy
- Groups
- Tramadol–dipyrone combination, tramadol alone, or dipyrone alone
- Concurrent analgesia
- Meloxicam for all dogs
- Dosing schedule
- Initial IV dose at the end of surgery, then oral dosing about eight hours later every eight hours for five days
- Main finding
- The combination provided better early postoperative pain control than either single agent
- Safety
- No clinically relevant adverse effects were reported
A new randomized clinical trial suggests a fixed-dose oral tramadol–dipyrone combination may offer better early postoperative analgesia than tramadol or dipyrone alone in dogs recovering from ovariohysterectomy and unilateral mastectomy. In the Frontiers in Veterinary Science study, 30 client-owned female dogs were assigned to one of three groups, and the combination arm showed better early pain control, a higher proportion of pain-free dogs during the early recovery window, and no clinically relevant adverse effects. (frontiersin.org)
The paper builds on earlier work from some of the same research line in canine surgical pain. A 2013 randomized controlled trial in dogs undergoing unilateral mastectomy with or without ovariohysterectomy found tramadol alone, tramadol plus dipyrone, and tramadol plus meloxicam all provided effective analgesia for most dogs over 24 hours. More recently, the same general concept was also studied in cats, where a Frontiers report in 2026 found fewer animals in the oral tramadol–dipyrone group needed rescue medication after ovariohysterectomy. Together, those studies point to sustained interest in whether combining these agents can improve perioperative pain control in small-animal practice. (pubmed.ncbi.nlm.nih.gov)
In the new canine trial, all dogs received meloxicam and an initial IV dose of the assigned analgesic at the end of surgery, then began oral treatment about eight hours later and continued every eight hours for five days. Pain was assessed with the Glasgow Composite Measure Pain Scale–Short Form, a dynamic interactive visual analog scale, and serum cortisol concentrations. Results showed pain scores fell over time in all groups, but dogs receiving dipyrone alone had higher Glasgow pain scores than the combination group on the afternoon of postoperative day 1. After oral treatment started, two dogs in the tramadol group and two in the dipyrone group required rescue morphine, while none in the combination group did. Cortisol stayed within the reference range in the combination group, while transient elevations were seen in the single-agent groups. (frontiersin.org)
The study also lands in the middle of a long-running debate about tramadol in dogs. Consensus guidance on canine osteoarthritis published in Frontiers described weaker evidence-based efficacy for tramadol than for several other adjunct options, and WSAVA educational material has gone further, stating tramadol should not be used as a standalone therapy for pain in dogs because evidence for reliable analgesia is limited. That makes the current findings more relevant as a multimodal story than as a tramadol endorsement by itself: the apparent benefit came from the combination protocol, not tramadol monotherapy. (frontiersin.org)
There’s also an important market and regulatory wrinkle for U.S. readers. Dipyrone, also called metamizole, is not a routine mainstream analgesic in U.S. companion-animal practice, even though FDA says the approved injectable animal drug Zimeta can be used extralabel in dogs under 21 CFR Part 530. The product studied here was Sindolor, a fixed-dose oral tramadol–dipyrone combination referenced in the paper, and that means the exact formulation studied may not map neatly onto what most U.S. veterinarians can prescribe or dispense today. Any clinical takeaways, then, have to be filtered through local availability, compounding considerations, and compliance obligations. (frontiersin.org)
Why it matters: For veterinary professionals, the practical question is what happens after discharge, especially for dogs recovering from painful soft-tissue surgery where the first 24 hours can determine whether a pet parent ends up calling back for uncontrolled pain, dysphoria concerns, or additional rescue medication. This trial suggests a scheduled oral combination may smooth that transition better than either drug alone, at least within a meloxicam-based multimodal plan. At the same time, the sample size was small, the procedures were specific, and all dogs received concurrent NSAID therapy, so the study doesn’t prove the combination should replace stronger opioid-centered protocols for every patient. It does, however, offer a potentially useful data point for clinicians looking to strengthen outpatient analgesia without relying on tramadol alone. (frontiersin.org)
What to watch: The next steps are likely larger comparative trials, clearer reporting on formulation and dosing portability across markets, and follow-up work that tests the combination against other multimodal discharge strategies rather than only against its component drugs. For U.S. practices, watch whether any additional regulatory, compounding, or commercial developments make oral dipyrone-containing protocols more accessible, because that will determine whether this evidence changes practice or remains mostly of academic interest. (fda.gov)